# Emerging non-factor therapies for hemophilia

## and their mechanisms of action




novo nordisk®

# Emerging non-factor therapies for hemophilia

## and their mechanisms of action

Replacement therapies using either plasma-derived or recombinant FVIII or FIX have been the foundation for restoring hemostasis in people with hemophilia.[1–3]

Novel therapeutic options are being investigated to reduce the burden of disease and treatment.[2]

- **In hemophilia A, FVIII is deficient. In hemophilia B, FIX is deficient.[1]**
- **These defects impair coagulation, leading to hemorrhage.[1]**

### Initiation

Following injury, tissue factor and FVIIa form a complex, which generates FXa. Together with FVa, FXa forms the prothrombinase complex, leading to minute amounts of thrombin generation.[2,4]




### Amplification

Thrombin activates platelets and multiple coagulation factors, including FV and FVIII.[2,4]






Clot formation

Normal coagulation



In hemophilia, factor deficiency impedes stable clot formation.[1]

### Propagation

Sequential formation of the tenase (FVIIIa/FIXa) and prothrombinase (FXa/FVa) complexes on the surface of the activated platelet drives a thrombin burst, leading to fibrinogen cleavage to fibrin, further platelet activation, and ultimately clot formation.[2–4]



- **In normal hemostasis, a complex system allows regulation of coagulation to prevent thrombosis.[2,5]**
- **The physiological anticoagulants involved in this system are potential targets for relieving the natural inhibition of coagulation to promote clot formation and limit bleeding in people with hemophilia.[2,5]**

## Initiation




**Tissue factor pathway inhibitor** controls the initiation phase by regulating the activity of FXa and the TF/FVIIa complex.[2,5]

## Amplification




## Propagation






Clot formation downregulated in normal hemostasis and hemophilia

- **Emerging non-factor therapies are being developed to block the natural inhibitors of coagulation or mimic the procoagulant activity of a missing clotting factor.[2,3]**
- **These therapies target various points of the coagulation cascade to restore thrombin generation despite FVIII or FIX deficiency.[2,3,5]**

## Initiation




**Anti-TFPI monoclonal antibodies** block TFPI and extend the initiation phase of coagulation, allowing further FXa and thrombin generation.[2,7–9]

## Amplification




## Propagation




Silencing of **anti-thrombin** synthesis through **siRNA** relieves inhibition of thrombin.[2,10]

**FVIII mimetics** are bi-specific antibodies that bridge FIXa and FX to mimic the function of activated FVIII.[2,11]

Modified **serpins** targeting **APC** relieve inhibition of FVa and FVIIIa.[6]



Clot formation

**APC**, activated protein C; **FII**, factor II; **FIIa**, activated factor II; **FIX**, factor IX; **FIXa**, activated factor IX; **FV**, factor V; **FVa**, activated factor V; **FVII**, factor VII; **FVIIa**, activated factor VII; **FVIII**, factor VIII; **FVIIIa**, activated factor VIII; **FX**, factor X; **FXa**, activated factor X; **II**, factor II; **IIa**, activated factor II; **IX**, factor IX; **IXa**, activated factor IX; **K1**, Kunitz 1; **K2**, Kunitz 2; **K3**, Kunitz 3; **siRNA**, short interfering RNA; **TF**, tissue factor; **TFPI**, tissue factor pathway inhibitor; **V**, factor V; **Va**, activated factor V; **VII**, factor VII; **VIIa**, activated factor VII; **VIII**, factor VIII; **VIIIa**, activated factor VIII; **X**, factor X; **Xa**, activated factor X.

## REFERENCES


1. Srivastava A *et al*. Guidelines for the management of hemophilia. *Haemophilia*. 2013;19(1):e1–e47.
2. Butterfield JSS *et al*. A Molecular Revolution in the Treatment of Hemophilia, *Mol Ther*. 2019;doi.org/10.1016/j.ymthe.2019.11.006.
3. Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. *Int J Hematol*. 2020;111(1):42–50.
4. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. *Thromb Haemost*. 2001;85(6):958–965.
5. Smith SA *et al*. How it all starts: Initiation of the clotting cascade. *Crit Rev Biochem Mol Biol*. 2015;50(4):326–336.
6. Polderdijk SGI *et al*. Design and characterization of an APC-specific serpin for the treatment of hemophilia. *Blood*. 2017; 129:105–113.
7. Hilden I *et al*. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. *Blood*. 2012;119:5871–5878.
8. Shapiro AD *et al*. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. *Blood*. 2019;134:1973–1982.
9. Cardinal M *et al*. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. *J Thromb Haemost*. 2018;16(9):1722–1731.
10. Sehgal A *et al*. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. *Nat Med*. 2015;21:492–497.
11. Shima M *et al*. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. *N Engl J Med*. 2016;374(21):2044–2053.


Illustrations of coagulation regulation in healthy subjects and patients with hemophilia are simplified, and do not claim to be exhaustive.

 Date of Preparation: April 2020.
Novo Nordisk Health Care AG, Zurich, Switzerland.

novo nordisk®